Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) Income from Continuing Operations (2016 - 2025)

Acro Biomedical has reported Income from Continuing Operations over the past 10 years, most recently at 42526.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 42526.0 for Q4 2025, up 498.44% from a year ago — trailing twelve months through Dec 2025 was 101146.0 (down 139.13% YoY), and the annual figure for FY2025 was 101146.0, down 139.13%.
  • Income from Continuing Operations for Q4 2025 was 42526.0 at Acro Biomedical, up from 117809.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for ACBM hit a ceiling of 2227578.0 in Q4 2021 and a floor of 4011322.0 in Q3 2022.
  • Median Income from Continuing Operations over the past 5 years was 88651.5 (2021), compared with a mean of 1321994.8.
  • Biggest five-year swings in Income from Continuing Operations: soared 3706.19% in 2021 and later crashed 6503.69% in 2022.
  • Acro Biomedical's Income from Continuing Operations stood at 2227578.0 in 2021, then crashed by 276.63% to 3934681.0 in 2022, then soared by 99.54% to 18240.0 in 2023, then surged by 41.49% to 10673.0 in 2024, then surged by 498.44% to 42526.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 42526.0 (Q4 2025), 117809.0 (Q3 2025), and 15562.0 (Q2 2025) per Business Quant data.